Bioventix PLC Share Price

Equities

BVXP

GB00B4QVDF07

Biotechnology & Medical Research

Market Closed - London S.E. 09:05:11 24/06/2024 pm IST 5-day change 1st Jan Change
4,425 GBX +1.72% Intraday chart for Bioventix PLC +2.91% +2.91%

Financials

Sales 2024 * 14M 17.78M 1.48B Sales 2025 * 15.1M 19.17M 1.6B Capitalization 231M 293M 24.47B
Net income 2024 * 8M 10.16M 847M Net income 2025 * 9M 11.43M 953M EV / Sales 2024 * 16.1 x
Net cash position 2024 * 6M 7.62M 636M Net cash position 2025 * 6.4M 8.13M 678M EV / Sales 2025 * 14.9 x
P/E ratio 2024 *
26.9 x
P/E ratio 2025 *
24.9 x
Employees 12
Yield 2024 *
3.64%
Yield 2025 *
3.89%
Free-Float 91.98%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.72%
1 week+2.91%
Current month+2.91%
1 month+2.91%
3 months-3.80%
6 months+2.91%
Current year+2.91%
More quotes
1 week
4 200.00
Extreme 4200
4 540.00
1 month
3 800.00
Extreme 3800
4 540.00
Current year
3 800.00
Extreme 3800
5 100.00
1 year
3 402.00
Extreme 3402
5 100.00
3 years
2 880.00
Extreme 2880
5 100.00
5 years
2 590.00
Extreme 2590
5 100.00
10 years
26.51
Extreme 26.51
5 100.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 23/03/23
Director of Finance/CFO 65 01/20/01
Members of the board TitleAgeSince
Chairman 64 26/04/26
Chief Executive Officer 65 23/03/23
Director/Board Member 71 25/14/25
More insiders
Date Price Change Volume
24/24/24 4,425 +1.72% 20,427
21/24/21 4,350 +0.58% 1,679
20/24/20 4,325 0.00% 807
19/24/19 4,325 +0.58% 1,316
18/24/18 4,300 0.00% 596

Delayed Quote London S.E., June 24, 2024 at 09:05 pm IST

More quotes
Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function, and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.
Calendar
More about the company

Annual profits - Rate of surprise